Pharmaceuticals - Pakistan

  • Pakistan
  • In 2024, the projected revenue in the Pharmaceuticals market in Pakistan is expected to reach a staggering US$1,712.00m.
  • Among the various markets, the largest one is Oncology Drugs, which is projected to have a market volume of US$199.90m in 2024.
  • Looking ahead, the revenue is expected to display an annual growth rate (CAGR 2024-2028) of 3.72%, resulting in a market volume of US$1,981.00m by 2028.
  • When compared globally, it is worth noting that United States is anticipated to generate the most revenue in the Pharmaceuticals market, with a projected revenue of US$636.90bn in 2024.
  • Pakistan's pharmaceutical market is experiencing a surge in demand for generic medicines due to their affordability and accessibility.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Pakistan, a country in South Asia, has been experiencing a steady growth in its Pharmaceuticals market in recent years.

Customer preferences:
The pharmaceuticals market in Pakistan is mainly driven by the demand from the local population for affordable and accessible medicines. The majority of the population in Pakistan is low-income and relies heavily on public healthcare facilities for their medical needs. Therefore, the demand for low-cost generic medicines is high in the country.

Trends in the market:
One of the major trends in the pharmaceuticals market in Pakistan is the increasing trend of outsourcing drug manufacturing to the country. Pakistan has a large pool of skilled labor and low labor costs, making it an attractive destination for pharmaceutical companies looking to reduce their manufacturing costs. This trend has led to an increase in the number of pharmaceutical companies setting up manufacturing facilities in Pakistan.Another trend in the market is the increasing focus on research and development (R&D) activities. The government of Pakistan has been taking steps to promote R&D in the pharmaceuticals sector by providing tax incentives and other benefits to companies engaged in R&D activities. This has led to an increase in the number of R&D centers and collaborations between local and international pharmaceutical companies.

Local special circumstances:
Pakistan has a large population of over 200 million people, which makes it an attractive market for pharmaceutical companies. However, the country faces several challenges in the pharmaceuticals sector, including a lack of proper regulatory oversight, a weak intellectual property regime, and a fragmented distribution network. These challenges have led to issues such as counterfeit drugs and a lack of access to essential medicines in some parts of the country.

Underlying macroeconomic factors:
The pharmaceuticals market in Pakistan is influenced by several macroeconomic factors, including the country's GDP growth rate, inflation rate, and government policies. The government of Pakistan has been taking steps to promote the pharmaceuticals sector by providing tax incentives, reducing tariffs on raw materials, and increasing public spending on healthcare. However, the country still faces challenges such as a weak infrastructure and a lack of skilled labor, which can hinder the growth of the pharmaceuticals sector.In conclusion, the pharmaceuticals market in Pakistan is growing steadily, driven by the demand for affordable and accessible medicines. The country's large population and low manufacturing costs make it an attractive destination for pharmaceutical companies, but challenges such as a weak regulatory regime and a fragmented distribution network need to be addressed to ensure sustained growth in the sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)